MGC Pharmaceuticals Limited NPV (DI) (MXC) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Jul 2023 07:00 AM
RNS
Reclassification of Psychedelic Compounds
30 Jun 2023 09:31 AM
RNS
Details of Company Address
30 Jun 2023 09:30 AM
RNS
Company Update
29 Jun 2023 10:22 AM
RNS
Results of Shareholder’s General Meeting
01 Jun 2023 07:30 AM
RNS
Appointment of Non-Executive Director
31 May 2023 07:00 AM
RNS
First CannEpil® delivered to UK patients
30 May 2023 07:01 AM
RNS
Corporate Update - Board and UK Adviser Changes
30 May 2023 07:00 AM
RNS
Dispatch of General Meeting Documents
18 May 2023 12:00 PM
RNS
Director/PDMR Shareholding
10 May 2023 05:05 PM
RNS
Director/PDMR Shareholding
02 May 2023 07:00 AM
RNS
Malta Production Facility Receives EU-GMP Approval
28 Apr 2023 07:13 AM
RNS
March 2023 Quarterly Activities and Cash Flow
13 Apr 2023 07:00 AM
RNS
Fundraise closed raising a total of £2,090,890
11 Apr 2023 07:01 AM
RNS
£1.2 million raised in a conditional Placing
11 Apr 2023 07:00 AM
RNS
CannEpil® available by Named Patient Request in UK
03 Apr 2023 07:00 AM
RNS
Approval to Develop and Research with Psilocybin
21 Mar 2023 09:05 AM
RNS
Second Price Monitoring Extn
21 Mar 2023 09:00 AM
RNS
Price Monitoring Extension
21 Mar 2023 07:00 AM
RNS
ArtemiC Listed as OTC Drug; AMC Places US$2m order
15 Mar 2023 04:35 PM
RNS
Price Monitoring Extension
15 Mar 2023 07:00 AM
RNS
First patient enrolled in MGC ZAM App
08 Mar 2023 09:00 AM
RNS
US$500,000 funding received under Mercer Facility
07 Mar 2023 07:00 AM
RNS
Completion of CimetrAT Mechanism of Action study
01 Mar 2023 07:02 AM
RNS
Appointment of UK Lead Broker and Change of Co Sec
28 Feb 2023 09:08 AM
RNS
Half-year Report
10 Feb 2023 08:45 AM
RNS
Updated Investor Presentation
03 Feb 2023 07:00 AM
RNS
Provision of US$600,000 funding and change of CFO
02 Feb 2023 07:00 AM
RNS
Extension of Convertible Securities Agreements
30 Jan 2023 07:00 AM
RNS
December 2022 Quarterly Activities and Cash Flow
23 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
23 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
16 Jan 2023 07:00 AM
RNS
Change of Adviser - SW4 Partners
11 Jan 2023 09:01 AM
RNS
Change in External Financial Auditor
10 Jan 2023 07:00 AM
RNS
Completion of CimetrAT Pre-clinical Trial
03 Jan 2023 07:00 AM
RNS
Internal Costs Review Completed and Board Change
28 Dec 2022 09:10 AM
RNS
A$800,000 funding received under Mercer Facility
08 Dec 2022 01:46 PM
EQS
MGC Pharmaceuticals delivers its largest-ever o...
07 Dec 2022 07:00 AM
RNS
Completion of CimetrA Efficacy Pre-clinical Trial
05 Dec 2022 07:00 AM
RNS
Delivery of US$1m order of ArtemiC to AMC Holdings
02 Dec 2022 07:00 AM
RNS
Publication of MGC Pharma Glioblastoma research
28 Nov 2022 07:00 AM
RNS
Result of AGM and Investor Presentation
22 Nov 2022 07:00 AM
RNS
Website Update
16 Nov 2022 09:00 AM
RNS
Notice of AGM
09 Nov 2022 10:20 AM
RNS
Application for Admission to Trading
31 Oct 2022 07:00 AM
RNS
September Quarterly Activities and Cash Flow
25 Oct 2022 07:00 AM
RNS
ArtemiC Support - Long COVID Clinical Study Resuls
20 Oct 2022 07:00 AM
RNS
Operations Update - Major Milestones Achieved
18 Oct 2022 09:00 AM
RNS
2022 AGM Notice of Meeting and Annual Report
05 Oct 2022 01:03 PM
RNS
Results of Shareholder's General Meeting
04 Oct 2022 07:00 AM
RNS
Appointment of UK Advisor and Company Update

MGC Pharmaceuticals is a biopharmaceutical company focused on researching, developing and supplying "plant-inspired" and cannabinoid-derived medicines to treat conditions in neurology, immunology and oncology. MGC Pharmaceuticals rebranded as Argent BioPharma.

MGC Pharmaceuticals share price is now listed on the Australian Securities Exchange under the ticker RGT.

UK 100

Latest directors dealings